Date of Report (Date of earliest event reported): February 7, 2019

OptimizeRx Corporation
(Exact name of registrant as specified in its charter)


Nevada   000-53605   26-1265381
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)


400 Water Street, Suite 200, Rochester, MI   48307
(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: 248.651.6568




(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company   ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐







SECTION 8 – Other Events


Item 8.01Other Events


On February 7, 2019, we issued a press release announcing the formation of a multi-specialty physician panel with the mission of improving the effectiveness of digital health communications delivered throughout the care continuum. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.


The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.


SECTION 9 – Financial Statements and Exhibits


Item 9.01Financial Statements and Exhibits


99.1 Press release, dated February 7, 2019







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


OptimizeRx Corporation  
/s/ Douglas Baker  
Douglas Baker  
Chief Financial Officer  
Date: February 8, 2019  



Exhibit 99.1




OptimizeRx Introduces OptimizeMDs, a “Voice of the Physician” Multi-Specialty Digital Health Panel


Panel encourages physicians to provide input on industry efforts to address and improve pharma-to-provider communication


ROCHESTER, Mich., (February 7, 2019) — OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health messaging for the pharmaceutical industry, has formed OptimizeMDs, a multi-specialty physician panel with the mission of improving the effectiveness of digital health communications delivered throughout the care continuum.


“OptimizeRx provides technology designed to streamline and improve communications between pharma/life sciences, providers and patients,” said Miriam Paramore, president of OptimizeRx. “We established OptimizeMDs as a way to gather important and timely information about the challenges physicians face with prescribing decisions, medication affordability and patient support. We expect the lessons learned from OptimizeMDs will help us further bridge the communication gaps between pharma and provider and patient, and ultimately improve affordability and adherence.”


Learning about these gaps in healthcare from the provider perspective, the professional most closely linked to the patient, is expected to provide powerful intelligence that pharmaceutical manufacturers and EHR vendors can use to improve how and when they digitally communicate.


Most pharmaceutical industry events geared towards better engagement with healthcare providers rarely provide insights directly from them. “At a recent pharma-hosted conference with over 4,000 attendees, I was surprised there was only one panel that represented the voice of physicians,” noted Paramore. “Through OptimizeMDs, we believe we can improve digital communication in this important area by giving voice to physicians serving patients at the point-of-care and beyond. We see this enhancing brand awareness and product launches by providing our clients timely access to valuable information and physician/patient feedback.”


More than 1,200 healthcare providers have already joined the panel. They represent a broad range of practice sizes and settings, allowing OptimizeMDs to provide statistically valid insights into key questions that pharma, healthcare IT and others are looking to address.


Physicians can join OptimizeMDs today by signing up at





About OptimizeRx


OptimizeRx® (NASDAQ: OPRX) is one of the nation’s leading providers of digital health messaging via electronic health records (EHRs), providing a direct channel for pharma companies to communicate with healthcare providers. The company’s cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information. The company’s network is comprised of leading EHR platforms like Allscripts, Amazing Charts and Quest, and provides more than half of the ambulatory patient market with access to these benefits within their workflow at the point-of-care. For more information, follow the company on Twitter, LinkedIn or visit


Important Cautions Regarding Forward Looking Statements


Certain information contained in this press release includes “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995, including statements related to the proposed public offering, the filing of the registration statement and potential market opportunity for our product candidates. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current expectations that involve risks, potential changes in circumstances, assumptions and uncertainties. Any or all of the forward-looking statements may turn out to be wrong, or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties as a result of various important factors, including the uncertainties related to market conditions, our ability to satisfy the closing conditions of the offering, the timing or occurrence of the closing, and the anticipated use of the proceeds of the offering, which could change as a result of market conditions or for other reasons. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, please refer to our prospectus supplement filed with the Securities and Exchange Commission (SEC) on December 17, 2018 under the heading “Risk Factors” and those documents incorporated by reference therein, which includes our Annual Report on Form 10-K filed with the SEC on March 8, 2018. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.


OptimizeRx Contact


Doug Baker, CFO

Tel (248) 651-6568 x807


Media Relations Contact


Nicole Brooks, Innsena Communications

(Tel) 860-800-2344


Investor Relations Contact


Ron Both, CMA

Tel (949) 432-7557